



Adagio Therapeutics Strengthens Management Team with Appointments of Eric Kimble as Chief Commercial Officer and Ed Campanaro as SVP of Clinical Operations

September 9, 2020

Waltham, MA - September 9, 2020 - Adagio Therapeutics, Inc., a company focused on the development of best-in-class antibodies to provide broad protection against SARS-CoV-2, SARS-CoV-1 and additional circulating bat coronaviruses, today announced it has strengthened its management team with the addition of Eric Kimble as Chief Commercial Officer and Ed Campanaro as Senior Vice President of Clinical Operations.

“At Adagio we are focused on advancing best-in-class antibodies against SARS-CoV-2 as well as future/impending coronaviruses as quickly as is humanly possible. We believe our antibodies offer a potentially better solution for COVID-19, one that can be administered twice a year while offering robust protection with limited side effects, and can also be used as a treatment for patients fighting the virus,” said Tillman Gerngross, Ph.D., CEO of Adagio. “Eric’s proven track record in developing and executing commercialization strategies and Ed’s expertise in advancing clinical development programs through to commercialization will help us achieve that goal. On behalf of our entire team I want to extend a warm welcome to both Eric and Ed.”

Mr. Kimble commented, “I have spent much of my career focused on commercializing novel and desperately-needed anti-infectives, and I am thrilled to work with this talented team to provide the world with an antibody solution that could address the current coronavirus as well as potential future outbreaks. In doing so, I hope to contribute to the path back to ‘normal’ by advancing this potential best-in-class product.”

“This is a tremendously dynamic and evolving time for planning and executing clinical trials aimed at preventing and treating COVID-19, and Adagio is rising to meet that challenge. I look forward to working closely with our medical and development teams to design our clinical strategy and execute our studies, as we aim to advance these class-leading monoclonal antibodies rapidly through our clinical trials,” said Mr. Campanaro.

Prior to joining Adagio, Mr. Kimble was the Chief Commercial Officer at Entasis Therapeutics where he developed commercialization strategies for the company’s two Phase 3 antibiotics. Prior to his role at Entasis, he held a variety of leadership roles at Cubist Pharmaceuticals, including Vice President of Sales & Marketing and Vice President of Program & Portfolio Management. At Cubist, Mr. Kimble led the U.S. Commercial team in the blockbuster commercialization of CUBICIN, the most successful IV antibiotic launch in history. Prior to joining Cubist, Mr. Kimble held numerous commercial roles at Biogen and Merck. Kimble received his M.B.A. from Harvard University and his B.A. from Brown University.

Mr. Campanaro has more than three decades of drug development experience spanning multiple biopharmaceutical companies and various therapeutic areas. Prior to joining Adagio, he was Senior Vice President of Clinical Operations at Artugen Therapeutics, where he helped to launch two first-in-human trials for two separate products. Prior to his work at Artugen, Mr. Campanaro was Senior Vice President of Clinical Operations at Arsanis, where he oversaw clinical operations, data management, and medical writing functions including CROs and vendors involved in the execution and analysis of a complex global Phase 2 ICU-based trial. Prior to Arsanis, Mr. Campanaro headed-up Clinical Operations and Data Management at bluebird bio, Inc., and before that, spent close to 15 years at Cubist Pharmaceuticals, where he led cross-functional teams through the successful execution and completion of global clinical development programs, leading to the successful marketing approvals for multiple novel antibiotics. Before entering the biopharmaceutical industry, Mr. Campanaro held hospital positions as an ICU registered nurse at The Massachusetts General Hospital and later as a Captain in the U.S. Air Force. Mr. Campanaro holds a M.S. from Georgetown University with a concentration in Clinical Research Administration, and a B.S.N. from The University of Massachusetts, Boston.

About Adagio

Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs, and can be used as both therapeutic and durable prophylactic treatments. Our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program is expected to enter the clinic by the end of 2020.

Contact:

Lindsay G. Deefholts
416-301-7966
ldeefholts@scientpr.com